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The coupling  of tumor-reactive antibodies  to  toxic  agents  as  a  way of directing 
such  agents  to  tumor  cells  in  vivo offers  the  promise  of highly  selective  therapy. 
During the past several years, there have been numerous reports describing the use of 
antibody coupled to drugs (reviewed in  1) and toxic peptides (immunotoxins)  (2-18) 
to kill  tumor cells in  vitro. The tumoricidal  effect of these  immunotoxins is highly 
specific and requires only minute doses. 
To explore  further  the  therapeutic  potential  of immunotoxins,  we chose  a  well- 
defined mouse tumor model (BCLx) (19). The tumor is a B cell leukemia ofmonoclonal 
origin, bearing surface IgM and IgD molecules (20, 21) that express a unique idiotype 
(22).  The tumor can be transferred with  1-10 cells  (17,  23),  and its growth pattern 
can be accurately measured by indirect  immunofluorescence using an anti-idiotypic 
(anti-Id) a antibody  (24).  Animals  bearing  the  tumor  survive  for  several  months, 
despite massive tumor burdens  (5 X  109-1  ×  101° cells/mouse). 
We have demonstrated  that  immunotoxins directed  against  the  immunoglobulin 
(Ig) on the surface of BCL1 cells can kill virtually all tumor cells in a  suspension of 
bone marrow or spleen (7, 17). In the present study, we treated mice bearing advanced 
BCL1  tumors  by  intravenous  administration  of tumor  reactive  immunotoxin.  The 
approach  was  to  eliminate  the  vast  majority of the  tumor  burden  by nonspecific 
cytoreductive  therapy.  The  residual  tumor  cells  were  then  killed  by  intravenous 
administration of an immunotoxin reactive with the idiotype or isotype of the surface 
Ig of the tumor cells. The results of these studies indicate that such immunotoxins are 
highly  effective at  inducing  prolonged  remissions  in  tumor-bearing mice provided 
that sufficient prior cytoreduction has been achieved. 
Materials and Methods 
The BCL1  Tumor.  BALB/c mice, 8-10 wk of age, were obtained from Cumberland Farms, 
Clinton, TN.  Mice were injected intravenously with 106 BCLa cells, and therapy was begun 6- 
8  wk later. At this point in time, the mice contained  1-2 ×  109 tumor cells in the spleens and 
2-4 ×  108 tumor cells per ml of blood. There were also large numbers of tumor cells in the liver 
(1 ×  109) and small numbers (~ 10-20%) of tumor cells in the bone marrow. Such mice would 
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survive another 4-6 wk in the absence of therapy. Before  the initiation of therapy, the mice 
were  staged  by  determining the  number of Id+  cells  in  the  spleens and blood.  This was 
accomplished  by  indirect  immunofluorescent staining with  rabbit  anti-Id and  fluorescein 
isothiocyanate (FITC) goat anti-rabbit Ig (GARIg) (22, 24). Stained cells were then quantified 
on  the  fluorescence-activated cell  sorter  (FACS)  (FACS  III;  B-D  FACS  Systems,  Becton, 
Dickinson & Co., Sunnyvale, CA). 
Antibodies 
ANTI-In.  Using a technique similar to that described by Levy and Dilly (25), nonsecreting 
BCL~ tumor cells were fused to nonproducing hypoxanthine-aminopterin-thymidine  sensitive 
myeloma cells (Sp2/0). A large portion of the hybridomas that survived the selection medium 
secreted  Id-positive IgMa into the medium. One BCL1 x  Sp2/0 hybridoma was recloned and 
then injected intraperitonealty into mineral oil-primed BALB/c mice. Large quantities of the 
IgMx  were  purified from  the  ascites  by conventional chromatographic techniques. Anti-Id 
antibody was  then  generated  by  immunizing rabbits with  the  BCL1 IgMx  and  removing 
antibodies directed  against  isotypic heavy  and  light  chain determinants by adsorption  on 
Sepharose-mouse Ig and Sepharose-MOPC- 104E (#, X). As demonstrated by radioimmunoassay 
and immunofluorescence staining, the anti-Id bound to the BCL1 IgMx and the BCL1 tumor 
cells but not to normal serum Ig, a panel of unrelated paraproteins, or to normal spleen cells 
from BALB/c mice (22, 24). The anti-Id antibody was affinity purified on Sepharose bound to 
the BCL1 IgMx. 
RABBIT ANTI-MOUSE // CHAIN (RABBIT ANTI-//).  Affinity-purified rabbit anti-//was prepared 
by  immunizing rabbits with  the  TEPC-1017  (//K) paraprotein.  The  anti-// antibodies were 
affinity purified on Sepharose-TEPC-1033 (//K) (26) and absorbed with Sepharose-mouse Ig to 
remove all anti-light chain specificities.  This anti-//reacts with the heavy chain of cell surface 
IgD on both normal mouse B cells and on BCLI cells (26). 
RABBIT ANTI-OVALBUMIN (ANTI-OVA).  The serum from rabbits immunized with commercial 
ovalbumin was affinity purified on Sepharose-OVA. These antibodies were used as controls in 
all experiments and, as determined by FACS analysis, did not bind to normal spleen cells or to 
BCLI cells. 
RABBIT ANTI-MOUSE I6 (RAMIG).  Rabbit serum was  prepared by immunizing rabbits with 
purified mouse Ig, and the specific antibody was eluted from Sepharose-mouse Ig as described 
previously (26). This antibody bound to both normal B cells and BCL1 cells. 
GOAT ANTI-RABBIT  IG (GARIG).  Goats were  immunized with purified rabbit IgG, and the 
antibody was  affinity purified on Sepharose-rabbit IgG. The affinity-purified antibody was 
conjugated to FITC as described previously (27). 
ANTI-TH','-I.  The 30-H-12 rat hybridoma cells (28) were obtained from Dr. Noel Warner, 
Becton, Dickinson & Co., Palo Alto, CA. The IgG~ antibodies secreted  by these cells bind to 
both Thy-1.1 and Thy-1.2 determinants. The medium from these hybridoma cells was treated 
with an equal volume of saturated ammonium sulfate, and the precipitate was centrifuged and 
resuspended at  1 mg/ml in phosphate-buffered saline, pH 7.3 (PBS). 
RABBIT ANTI-MOUSE  y CHAIN.  F(ab')2 fragments of rabbit anti-mouse y chain [F(ab')2 rabbit 
anti-mouse y] were prepared as described previously (29) Fragments were conjugated to FITC 
(27). 
Preparation of Immunotoxins.  Antibodies were conjugated to the A chain of ricin as described 
previously (7). Briefly,  the A chain from Ricinus coramunis agglutinin II (Vector Laboratories, 
Burlingame, CA) was isolated by ion exchange chromatography after reduction of the disulfide 
bond that links the A chain to the B chain. The concentrated ricin A chain was stored in 0.05% 
2-mercaptoethanol. Thiol groups were introduced into affinity-purified antibodies by using a 
30-fold  excess  of  N-succinimidyl-3-(3-pyridyldithio)-propionate (SPDP)  (Pharmacia  Fine 
Chemicals, Uppsala, Sweden). A fivefold  molar excess of ricin A chain was mixed with the 
thiolated antibodies, and the mixture was dialyzed extensively against PBS, pH 7.8, to initiate 
disulfide exchange-mediated coupling of ricin A chain to the antibody. The antibody-A chain 
conjugates were chromatographed on Sephacryl-200 to remove free A chain and the majority 
of the uncoupled antibody. The conjugates were evaluated and tested by radioimmunoassay 
(7)  and by analysis on sodium dodecyl sulfate-polyacrylamide gels. The antibody-A chain 
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Total  Lymphoid Irradiation (TLI)  (30,  31).  X  rays were  delivered by a  General Electric 
Maxitron 300  (General Electric Co.,  Wilmington, MA) at a rate of 60-70 tad/minute. Mice 
received a total of 200 rad per treatment and a total of 8-10 treatments over a period of 8-10 
d. The source-to-skin distance was 72 cm, and 2.0 mm Cu filters  were used. Dosimetry was 
verified using a  calibrating ionizing chamber and by lithium fluoride thermoluminescence 
dosimeter. BALB/c mice were anesthetized with nembutal at a dose of 70 ~g/g body weight 
and were positioned in the lead apparatus described by Slavin, et al. (30). The major lymph 
nodes, thymus, and spleen were exposed to the x rays.  The majority of the skull,  ribs, lungs, 
hind legs, and tails were shielded with lead. 
Splenectomy.  TLI-conditioned mice  were  anesthetized  with  nembutal at  70  #g/g  body 
weight. The spleens were exposed through a midline abdominal incision, the pedicle was tied 
off with 00 silk, and the spleens were excised.  The incision was closed  with metal clips.  The 
clips were allowed to remain in place for the duration of the experiments. 
Indirect Immunofluorescence and Analysis on the FA CS.  Indirect immunofluorescence  analysis was 
performed as described previously (22, 24). Briefly, cells suspended in PBS containing 10 mM 
sodium azide were treated with optimum concentrations  of the primary antibodies (rabbit anti- 
8, rabbit anti-Id, RAMIg, rabbit anti-OVA, normal rat IgG, or monoclonal rat anti-Thy-1) for 
15 min at 4°(3. Cells were then washed and resuspended in PBS-azide containing  either FITC- 
GARIg or  FITC-F(ab')2 R  anti-mouse y.  After a  10-min incubation on  ice,  the cells  were 
washed twice in PBS-azide and fixed at 4°C in 4% buffered paraformaldehyde. For analysis, 
the cells were centrifuged and resuspended in PBS.  The labeled cells were  analyzed on the 
FACS. A laser light of 488 nm was used at an intensity of 300 MV. Living and dead cells were 
distinguished by near-forward angle light scatter; dead cells were excluded from the analysis. 
The fluorescent signal was determined with a photomultiplier potential of 500 V  and a gain 
setting of 4. Fluorescent and scatter signals were standardized daily by using gluteraldehyde- 
fixed chicken erythrocytes. 
Administration of Immunotoxin and Stagzng of Treated Animals.  After 8-10 doses of 200 rad TLI 
(± splenectomy), animals were injected intraveneously  with two doses of 20 #g of immunotoxin 
5-7  d  apart.  At  weekly  or  biweekly  intervals thereafter,  mice  were  bled  by  retro-orbital 
punctures, and the white cell  count was determined. After leukemic relapse, cells  from the 
peripheral blood were  stained with rabbit anti-Id and FITC-GARIg to confirm their tumor 
origin. 
Results 
Effect of TLI on Regression of the  Tumor.  As shown in Fig.  1, after 8-10 fractionated 
doses  of 200  rad TLI, the  number of tumor cells in both  the  spleen and blood of 
tumor-bearing mice was reduced by 90-95%. Without further treatment, the levels of 
Id  +  ceils  in  the  spleen  began  to  increase  within  a  week  and  reached  50-80%  of 
pretreatment levels 1-2 wk after the termination of TLI. Id  + cells were detectable in 
the blood 1.5-2 wk after the completion of TLI and reached pretreatment levels 2 wk 
later. The rapid relapses indicated the persistence of large numbers of tumor cells in 
the spleen, liver, and bone marrow. 
Effect  of Immunotoxins after  TLL  Because of the rapid reappearance of tumor cells 
in the spleen and blood, immunotoxins were  injected within several days after the 
completion of TLI. Although cytoreduction was optimum at  this time, we estimate 
that  108-109  tumor cells remained in the  mice.  One of two  types of immunotoxin 
were  then  injected  into  the  TLI-conditioned mice.  The  first  was  a  rabbit  anti-Id 
immunotoxin that was specific for the BCL1 tumor cells, as demonstrated previously 
by in vitro studies  (7).  The second immunotoxin was  a  rabbit anti-8 that  is  not  a 
tumor-specific antibody. Nevertheless, the levels of serum IgD in mice are very low 
(32,  33),  there  are  few  B  cells  remaining in  TLI-conditioned mice  (31),  and  the 1800  IN  VIVO THERAPY  OF  A  MURINE B  CELL TUMOR 
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Ftc.  1.  Effect of TLI on elimination of BCLj tumor cells from the spleens  and blood of tumor- 
bearing mice. Mice were treated with nine daily doses of 200 rad TLI, and the spleens and blood of 
the animals were monitored for the presence  of Id  + tumor cells. Q, x  10 -s cells/spleen; O, X  I0 .7 
cells/ml blood. 
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Fio.  2.  The effect of immunotoxin on the reappearance of tumor cells in the spleens of BCL1 mice 
after nine doses of 200 rad TLI. After TLI, mice were injected with a single  20-gg dose of either 
rabbit anti-OVA-A chain, rabbit anti-Id-A chain, or rabbit  anti-mouse 6-A chain. An additional 
group was not injected. At 7 and 14 d after TLI, the mice were killed and the spleens were examined 
for Id  + cells. There were four mice per group,  r-n, no treatment; ~, anti-OVA-A; ~, anti-Id-A; I, 
anti-8-A. 
residual  B  cells lack surface IgD (R.  May and  E. Vitetta, manuscript  in preparation). 
Therefore,  the  rabbit  anti-6  immunotoxin  was  highly selective for  the  BCL1  tumor 
cells. Moreover, any normal B  cells that  would be killed during administration  of this 
immunotoxin  would be reconstituted  from  stem  cells in  the shielded  portions of the 
bone marrow.  As shown in Fig. 2, the administration  of either of these immunotoxins 
caused  a  measurable  delay  in  the  reappearance  of tumor  cells in  the  spleens  of the 
treated  mice.  However,  by  4  wk  after  treatment  (data  not  shown),  these  mice  had 
relapsed with progressive BCLa disease. These experiments  indicated  that  the admin- 
istration of immunotoxin  delayed relapse but  that  significant numbers  of tumor cells 
escaped  the effect of the immunotoxin  and  eventually repopulated  the spleens of the 
treated  mice. 
Effect of Immunotoxins after TLI and Splenectomy.  Rather  than  increase the amount  of K.  A.  KROLICK, J.  w.  UHR,  S.  SLAVIN,  AND  E.  S.  VITETTA  1801 
immunotoxin  administered,  we  chose  to  further  reduce  the  tumor  burden  before 
treatment with immunotoxin. Therefore, TLI-conditioned mice were splenectomized 
2 d  after the completion of TLI. Postsurgical survival of these mice was >90%.  2 d 
after splenectomy, mice were injected with 20 #g of specific or control immunotoxin 
or were left untreated.  The injections were repeated  1 wk later. As shown in Fig.  3, 
control mice (untreated or injected with rabbit anti-OVA-A chain)  showed elevated 
white counts in  the blood 4  wk after the completion of TLI (and splenectomy) and 
died 2-3 wk later. At the peak of leukemia, the blood cells from these mice were 70- 
80% Id  +. In contrast, the mice treated with rabbit anti-8-A chain showed no reemerg- 
ence of leukemic cells in the blood for a period of 14 wk after TLI, at which point the 
experiment was terminated.  Furthermore, peripheral blood cells were obtained from 
nine mice treated with rabbit anti-mouse 8-A chain at  10 wk and again at 14 wk after 
completion of TLI. The blood samples were pooled, and 0.5 ml (containing 3  ×  106 
cells)  was  injected  into  each  of three  normal  recipients.  Recipients  have remained 
tumor free for the 6  mo of observation after adoptive transfer (data not shown).  In 
comparing the data in Figs.  2 and 3, it is evident that one of the critical features in 
successful immunotoxin therapy is sufficient nonspecific cytoreduction of the tumor 
mass before immunotoxin administration.  As shown in Table I, similar experiments 
were performed with  a  total of 87  mice, and  the average remission time after TLI, 
splenectomy,  and  anti-6  immunotoxin  therapy  (38  mice)  was  significantly  greater 
than  after  nonspecific  cytoreduction  alone  (29  mice)  or  nonspecific  cytoreduction 
followed by control immunotoxin (20 mice). There were, however, instances in which 
late leukemic relapses were observed in mice treated with rabbit anti-mouse 8-A chain 
(57%  of the  mice relapsed).  Nevertheless,  in  every mouse  treated  with  the  specific 
immunotoxin,  there  was  a  significant  prolongation  of remission.  In  three  of four 
experiments, the mice appeared tumor free at  12-16 wk. It is possible, therefore, that 
these mice were cured.  We do not know the reasons for the relapses observed in one 
of the experiments. The most likely causes are differences in the extent of nonspecific 
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FxG.  3.  Effect  of TLI, splenectomy, and  administration of immunotoxin on  leukemic  relapse of 
BCLl-bearing mice. After nine doses of TLI and splenectomy, mice were injected with two doses of 
20  p.g of anti-8 or control  immunotoxin or were not  injected.  There were nine  mice per group. 
Leukemic  relapse was monitored  by  determining the  number of white cells  in  the  blood of the 
treated mice.  The control mice were all  dead at  7 wk after TLI. The rabbit anti-mouse 6-A chain- 
treated group was monitored for a  period of 14 wk post-TLI, at which point the experiment was 
terminated. O, no treatment; m, anti-OVA-A; O, anti-8-A. 1802  IN  VIVO TttERAPY  OF A  MURINE  B CELl. TUMOR 
TABLE  [ 
Effect of Immunotoxin on the Prevention of Leukemic Relapse in Mice Treated 
with TLI and Splenectomy 
A  Individual Experiments 
Number of  Average remission time in weeks* 
Experiment  mice/group  No treatment  Anti-OVA-A  Anti-&A 
1  9  4  4  14z~ 
2  4  4  4  12:~ 
3  18  4  ND§  8 
4  7  6  6  1614 
B  Summary 
Treatment  Number of Mice  Average remission 
time in weeks 
None  29  4.5 
Anti-OVA-A  20  3.8 
Anti-6-A  38  11.2¶ 
* End of remission defined as >2.5 ×  10  T leukocytes/ml. 
:~ No relapses observed, at which point experiments were terminated. 
~ Not done. 
Experiment still in progress. 
¶  Estimates of average remission time are minimum estimates because experi- 
ments  1, 2, and 4  were terminated or are in progress. 
cytoreduction and/or  differences among the batches of rabbit anti-mouse 6-A chain 
(affinity differences ?)  that were used during the course of these experiments. 
Effect of TLI, Splenectomy,  and Treatment  with Unconjugated Antibody.  There are reports 
indicating that  administration of antibody alone may be effective in the therapy of 
various  types  of tumors  (18,  34-41).  It  was  important,  therefore,  to  compare  the 
ability of conjugated  vs.  unconjugated  rabbit  anti-mouse  ~  to  induce  remission  in 
BCL-bearing  mice after TLI and splenectomy. As seen in Fig. 4, mice injected with 
rabbit anti-mouse 6-A chain showed no evidence of tumor cells in the blood, whereas 
animals injected with identical doses of antibody alone showed early leukemic relapses. 
There  was  no  significant  difference  between  the  animals  receiving no  injection  or 
administration of anti-6 alone (data not shown). These results emphasize the advan- 
tage of the immunotoxin compared with antibody alone. It is possible, of course, that 
administration  of very  large  amounts  of unconjugated  anti-6  might  have  had  an 
inhibitory effect on tumor growth. 
Immunofluorescence  Analysis of Cells  Obtained from  Mice in Remission.  Because animals 
had  been  treated  with  an  antibody-A chain  conjugate  directed against  cell surface 
IgD, it was of interest to determine whether mice in remission had  normal numbers 
of IgD-bearing B cells in their blood. Therefore,  14 wk after the completion of therapy 
(TLI, splenectomy, and  treatment  with  anti-~ immunotoxin),  peripheral blood cells 
from mice in remission were stained with either rabbit anti-mouse 6, rabbit anti-Id or 
monoclonal rat anti-Thy-1, and the appropriate secondary fluoresceinated antibody. 
Cells from normal BALB/c mice were stained in parallel. As shown in Table II, mice 
in  remission contained  higher percentages and  absolute numbers  of IgD  +  B  cells in 
their blood than  normal  mice.  Id  + ceils were not  detectable. The number  of T  cells 1803 
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Fro.  4.  The effect  of anti-8-A chain or anti-8 alone on the reappearance of leukemia in  BCLr 
bearing mice. After TLI and splenectomy, mice were injected with two doses, 1 wk apart, of 20 #g 
of either conjugated  or  unconjugated  antibody,  and  the  number of peripheral  blood  cells  was 
determined at 3 and 5 wk after TLI. There were four mice per group, m  L  anti-&A; m, anti-& 
TABLE  II 
Immunofluorescence Analysts of Pertpheral Blood Lymphocytes  from Mice in 
Remission 
Staining antibody 
Percent of PBL that stain 
Mice in remission*  Normal mice 
Anti-8  42  29 
Anti-Thy- 1  55  66 
Anti-Id  3  4 
Normal Ig  3  3 
* Blood counts ranged from  1-2  X  10  v cells/ml;  in normal mice such counts 
are 0.5-1  X  107 cells/ml. 
was normal. An increase in B lymphocytes in the blood has previously been observed 
in mice that have undergone TLI (31). These results indicate that despite the extensive 
immunosuppression resulting from TLI, splenectomy, and treatment  with an anti-6 
immunotoxin (potentially reactive with most normal B cells),  there was reconstitution 
of the IgD  + B cell compartment presumably from stem cells  in the bone marrow. 
Discussion 
The present  studies  have shown  that  in  vivo administration  of an  immunotoxin 
that was reactive with, but not specific for, a  tumor cell  (antibody to the ~$ chain of 
IgD) was instrumental  in inducing prolonged remissions and possible eradication of 
a murine B cell leukemia. The strategy was to use mice with enormous tumor burdens 
(>3  X  10  9  cells),  to reduce the  massive tumor burden  by nonspecific cytoreduction 
(fractionated total lymphoid irradiation and splenectomy), and to then administer a 
tumor-reactive  immunotoxin  to  kill  the  remaining tumor cells.  The success of this 
approach  is  illustrated  by  the  fact  that  each  of the  38  animals  so  treated  had  a 
significant  remission and  that  in  three of four experiments  (representing about one- 
half  the  mice)  the  duration  of  the  remission  was  12-16  wk,  at  which  time  the 1804  IN VIVO THERAPY OF A MURINE B CELL TUMOR 
experiments  were  terminated  or are  currently in  progress.  BCLl-bearing mice sub- 
jected to nonspecific cytoreduction and injection with anti-OVA immunotoxin or no 
immunotoxin were all dead 7 wk after splenectomy. In addition, transfer of peripheral 
blood cells  from animals in prolonged remission into normal syngeneic mice did not 
cause tumor in  the  recipients  at  a  time after transfer when  1-10  BCL1 cells  would 
have caused tumor in the recipients.  It could be argued that an anti-tumor response 
was  transferred  with  the  peripheral  blood  cells  and  that  this  putative  immunity 
(although highly diluted in the normal recipients)  might still  be effective in suppress- 
ing growth of a small number of tumor cells.  In addition, although mice in remission 
might  not  have  tumor cells  in  the  blood, they may still  harbor such  cells  in  other 
organs,  e.g.  lymph  nodes,  brain,  testes,  etc.  This  may  indeed  be  the  case  after 
splenectomy. Thus, we are unable to conclude at this time whether there was a small 
number of tumor cells held in check by a host anti-tumor immune response or whether 
the mice were tumor free. 
Our  initial  in  vitro  studies  were  performed  with  an  anti-Id  immunotoxin  to 
specifically kill  BCL1 cells,  and our preliminary in vivo results with anti-Id immuno- 
toxin were encouraging. However, antibody against the BCL1 Id is difficult to generate 
in  large  quantities,  and  its  use  is  restricted  to  the  BCL1  tumor.  In  contrast,  large 
amounts of heterologous (29) or monoclonal (42) anti-6 antibody can be easily raised. 
Anti-6  immunotoxins  should  be  effective  in  treating  mice  bearing  BCL1  tumors 
because (a) BCLa tumor cells bear IgD (20, 21);  (b) serum IgD levels in the mouse are 
extremely low (32,  33);  (c)  IgD-bearing normal B cells  are virtually eliminated after 
TLI (31);  and (d) IgD- pre-B cells, immature B cells  (IgM+IgD-), or stem cells should 
repopulate  the  B  cell  compartment after  the elimination  of mature  IgD-bearing B 
cells  by TLI and immunotoxin therapy. The success of this approach in the present 
experiment  has important  implications for the potential  treatment  of human B cell 
neoplasms such as chronic lymphocytic leukemia or non-Hodgkins lymphomas. Thus, 
the  majority of such  tumors  bear  IgD  (43).  Serum  IgD levels  are  also  low  in  the 
human  (44)  and  probably  even  lower  in  patients  with  B  cell  tumors  who  are 
immunosuppressed because of the tumor (45) and/or because of chemotherapy. Thus, 
an anti-IgD immunotoxin, in contrast to anti-Id immunotoxin, might be viewed as a 
potentially "universal" immunotoxin for the management of a large portion of human 
B cell tumors. 
We attribute the relative effectiveness of in vivo therapy with immunotoxins in the 
BCL1  tumor model to a  number of factors:  (a)  BCL1 cells  are highly susceptible  to 
killing by the immunotoxins in  vitro  (7,  17); (b)  the  immunotoxins used  remained 
biologically active after admixture with  fresh mouse serum, i.e.,  significant disulfide 
exchange or inactivation by serum enzymes did not occur; (c) earlier in vitro results 
suggest  that  all  BCL1 tumor cells  express surface Ig (17);  (d)  extensive  nonspecific 
cytoreduction could be achieved and  its  degree of effectiveness could be accurately 
measured  by indirect  immunofluorescence using the anti-Id reagent  in  conjunction 
with  FACS  analysis;  (e)  the  amount  of immunotoxin  needed  to  kill  a  particular 
number of BCLa cells could also be estimated based on in vitro experiments; and (f) 
BCLl-bearing mice are characteristically in an immunosuppressed state (46),  so that 
after  TLI,  which  is  in  itself  immunosuppressive  (31),  tumor-bearing  mice  cannot 
mount an antibody response to the heterologous immunotoxin. Thus, the characteri- 
zation  of  the  BCLx  tumor  model  and  the  results  of  the  in  vitro  studies  using K. A.  KROLICK, J.  W.  UHR,  S.  SLAVIN, AND E.  S.  VITETTA  1805 
immunotoxins formed a  firm foundation  for the development of a  rational  in  vivo 
approach. 
There have been several reports of in vivo use of immunotoxins in which some anti- 
tumor effects were obtained.  One of the  most  provocative of the  studies  is that  of 
Moolton  et  al.  (4),  who conjugated  whole  diphtheria  toxin  to antibodies  raised  to 
SV40-transformed  cells  and  affinity purified  the  antibody  on  such  cells.  Repeated 
injections  with  these  conjugates  caused  long-lasting  remissions  in  a  proportion  of 
hamsters  bearing  SV40-induced  lymphomas but  did  not  effect  established  SV40- 
induced sarcomas. In more recent experiments performed by Blythman et al. (16), T 
lymphoma cells  and  anti-Thy-l.2-ricin  A  chain  conjugates  were  injected  into  the 
peritoneal  cavity of mice at  virtually  the  same  time.  A  significant  number of the 
treated animals failed to develop tumors. In the studies of Trowbridge and Domingo 
(18),  nude  mice  carrying  a  human  melanoma  tumor  were  treated  with  an  anti- 
transferrin receptor antibody alone or with the antibody coupled to ricin A chain. It 
was  found  that  in  either  case  the  tumor  was  eliminated.  These  results  did  not, 
however, indicate a  functional role for the toxic portion of the immunotoxin. 
The present studies also emphasize the advantage of an immunotoxin compared to 
antibody  itself for in  vivo  therapy.  Unconjugated  anti-8  antibody  did  not  induce 
remission  in  mice  bearing  the  BCL~  tumor.  Nevertheless,  results  of therapy  with 
antibody alone or in combination with added complement have been encouraging in 
some other tumor systems (18, 34-41). The most successful of these experiments have 
involved protocols in which antibody is given simultaneously with or shortly after the 
injection of tumor cells so that tumor burdens are extremely small. Such results have 
been  described  by Lanier et  al.  (36),  who  demonstrated  that  administration  of an 
anti-Id prolonged the survival of mice bearing a B cell tumor. Kirsch and Hammerling 
(40) showed that high doses of monoclonal antibodies would inhibit the growth of the 
T  cell  tumor  ASL.1,  but  only  when  antibody  was  given  within  24  h  of  tumor 
inoculation.  Trowbridge  and  Domingo  (18),  using a  monoclonal  antibody reactive 
with  a  human  melanoma  growing  in  nude  mice,  and  Bernstein  et  al.  (35),  using 
monoclonal anti-Thy-1 antibodies in AKR mice bearing thymomas, induced curtail- 
ment  of tumor growth  in  a  high  proportion  of animals.  In humans with  leukemia, 
monoclonal or conventional antibodies  reactive with tumor cells caused substantial 
but transient decreases in tumor growth (34, 37-39, 41). It is probable, therefore, that 
a proportion of tumors are susceptible to this type of therapy because of complement- 
mediated killing, removal of tumor cells by the reticuloendothelial system, or through 
a cell-mediated defense mechanism. However, large amounts of Ig must be used, and 
it  is  likely that  the  host  will  eventually  respond  with  an  antibody response to  the 
heterologous Ig. In the case of monoclonal antibodies, the response could include an 
anti-idiotypic component. The advantages of using immunotoxins are that  (a) much 
smaller  amounts  of antibodies  can  be  used;  (b)  under  optimum  conditions  every 
tumor cell might be susceptible to killing by an immunotoxin that binds to it;  and 
(c) normal B cells that are specifically reactive with determinants on the immunotoxin 
(via the  B  cell's antigen-specific receptors)  might  be killed  by this contact,  thereby 
abrogating a  potential antibody response to the immunotoxin. 
There are a number of potential problems in considering immunotoxin therapy for 
human  tumors  beyond  the  problems  of toxicity,  precise  quantification  of tumor 
burden, and amount of immunotoxin to be administered. Thus, immunotoxins in the 1806  IN VIVO TttERAPY OF A MURINE B CELL TUMOR 
systemic circulation might not be able to reach tumor cells in solid tumors, particularly 
in  those  with  a  large  connective  tissue  component.  All  the  cells  from  a  particular 
tumor might not bear the relevant  determinant,  and, even if they do, the emergence 
of immunotoxin-resistant clones might occur at a significant incidence. These resistant 
clones could lack the surface antigen  in question,  be unable  to transport  the immu- 
notoxin into the cell, or be resistant to the lethal effects of the A chain. Large amounts 
of circulating tumor antigen  might compete successfully with the immunotoxins for 
surface antigen  on the tumor cells.  Another potential  problem  is the cross-reactivity 
of monoclonal anti-tumor antibodies with normal tissues. Considering the fact that a 
few immunotoxin  molecules can kill a  cell, modest cross-reactions could cause tissue 
damage.  In addition,  Fc binding  to certain  types  of normal  cells  might  also  cause 
nonspecific toxicity in vivo. We therefore believe that it is important to obtain further 
information  from  experiments  with  animal  models  before  using  immunotoxins  in 
humans. 
Summary 
Prolonged remissions were induced in mice bearing advanced BCL1 tumors by the 
combined  approach  of nonspecific  cytoreductive  therapy  and  administration  of a 
tumor-reactive immunotoxin. Thus, the vast majority of the tumor cells (~95%) were 
first  killed  by  nonspecific  cytoreductive  therapy  using  total  lymphoid  irradiation 
(TLI) and splenectomy. The residual tumor cells were then eliminated by intravenous 
administration  of an anti-3 immunotoxin.  In three of four experiments,  all  animals 
treated  in the above fashion appeared tumor free  12-16 wk later.  In one experiment, 
blood cells from the mice in remission were transferred  to normal BALB/c recipients, 
and  the  latter  animals  have  not  developed  detectable  tumor  for  the  6  mo  of 
observation.  Because  1-10  adoptively  transferred  BCL1  cells  will  cause  tumor  in 
normal  BALB/c mice by  12 wk,  the  inability  to transfer  tumor to recipients  might 
indicate  that  the  donor animals  were  tumor  free.  In the  remainder  of the  animals 
treated with the tumor-reactive immunotoxin there was a substantial  remission in all 
animals, but the disease eventually reappeared.  In contrast, all mice treated with the 
control  immunotoxin  or antibody  alone  relapsed  significantly  earlier  (3-4 wk after 
splenectomy). 
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